108 related articles for article (PubMed ID: 3754490)
1. Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Abrams RA; Hanson G; Hansen RM; Anderson T
Cancer Treat Rep; 1986 Apr; 70(4):535. PubMed ID: 3754490
[No Abstract] [Full Text] [Related]
2. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
[No Abstract] [Full Text] [Related]
3. Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Miller LP; Miller DR; Tan CT
Cancer Treat Rep; 1983 May; 67(5):439-43. PubMed ID: 6189604
[No Abstract] [Full Text] [Related]
4. Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Letendre L; Hinemann V; Hoagland HC; Kovach JS
Med Pediatr Oncol; 1985; 13(4):232-4. PubMed ID: 3839284
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
6. Amsacrine with high-dose cytarabine in acute leukemia.
Zittoun R; Bury J; Stryckmans P; Lowenberg B; Peetermans M; Rozendaal KY; Haanen C; Kerkhofs M; Jehn U; Willemze R
Cancer Treat Rep; 1985 Dec; 69(12):1447-8. PubMed ID: 3841026
[No Abstract] [Full Text] [Related]
7. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
8. Malignant histiocytosis resistant to anthracycline. Response to intensive treatment with etoposide and amsacrine.
Abrams RA; Hanson G; Hansen R; Baumann MA; Anderson T
Arch Intern Med; 1985 Apr; 145(4):742-3. PubMed ID: 3872645
[TBL] [Abstract][Full Text] [Related]
9. Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Arlin ZA
Cancer Treat Rep; 1983 Nov; 67(11):967-70. PubMed ID: 6357436
[No Abstract] [Full Text] [Related]
10. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
Bern MM; Wallach SR; Arkin CF; Lokich JJ; Huberman MS; Anderson NR; Corkery JC; Paul SD; Phillips DF; Sonneborn HA
Cancer Treat Rep; 1987 Feb; 71(2):201-3. PubMed ID: 3802115
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
[TBL] [Abstract][Full Text] [Related]
12. Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Arlin ZA
J Clin Oncol; 1985 Jan; 3(1):128. PubMed ID: 3838101
[No Abstract] [Full Text] [Related]
13. [AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Büchner T
Onkologie; 1985 Jun; 8(3):181-4. PubMed ID: 3895100
[TBL] [Abstract][Full Text] [Related]
14. [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Hiddemann W; Achterrath W; Urbanitz D; Preusser P; Balleisen L; Kirchhof B; Stenzinger W; Büchner T
Onkologie; 1984 Aug; 7(4):214-6. PubMed ID: 6384864
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
Amrein PC; Richards F; Coleman M; Poulin RF; Holland JF; Weinberg V; Perry M
Cancer Treat Rep; 1984 Jun; 68(6):923-4. PubMed ID: 6329510
[No Abstract] [Full Text] [Related]
16. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
Amrein PC; Coleman M; Richards F; Poulin RF; Berkowitz I; Kennedy BJ; Green M; Herschkopf R; Rafla S
Cancer Treat Rep; 1983 Nov; 67(11):1043-4. PubMed ID: 6688967
[No Abstract] [Full Text] [Related]
18. Amsacrine (AMSA)--a clinical review.
Louie AC; Issell BF
J Clin Oncol; 1985 Apr; 3(4):562-92. PubMed ID: 3884748
[No Abstract] [Full Text] [Related]
19. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Zander AR; Vellekoop L; Dicke KA; Keating MJ; McCredie KB; Legha SS; Spitzer G; Verma D; Bodey GP
Cancer Treat Rep; 1982 Nov; 66(11):1991-2. PubMed ID: 6754077
[No Abstract] [Full Text] [Related]
20. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
